182P Cancer vaccines based on whole-tumor-lysate or neoepitopes with validated HLA-binding outperform those with predicted HLA-binding affinity. (December 2022) - Kandalaft, L.; Fritah, H.; Graciotti, M.; Chiang, C.; Petremand, R.; Guillaume, P.; Schmidt, J.; Stevenson, B.; Gfeller, D.; Harari, A.